Our study showed a reduced prevalence of NAFLD in patients treated with GLP-1 receptor agonists and SGLT2 inhibitors, suggesting a potential protective effect. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.